Abstract
Severe symptomatic tricuspid regurgitation (TR) with right heart failure is associated with significant morbidity and mortality. Medical therapy is often ineffective and surgical correction is not feasible due to prohibitive perioperative risk. Transcatheter caval valve implantation (CAVI) is an evolving therapeutic option for this condition. It refers to the heterotopic placement of a valve into the inferior vena cava alone or with a second valve in the superior vena cava to restrict the backflow from the failing tricuspid valve. We hereby describe a patient with previous mitral valve surgery with chronic severe TR who underwent successful CAVI at our institute.
| Original language | English |
|---|---|
| Pages (from-to) | 365-368 |
| Number of pages | 4 |
| Journal | Annals of Cardiac Anaesthesia |
| Volume | 24 |
| Issue number | 3 |
| DOIs | |
| Publication status | Published - Jul 2021 |
| Externally published | Yes |
UN SDGs
This output contributes to the following UN Sustainable Development Goals (SDGs)
-
SDG 3 Good Health and Well-being
Keywords
- Caval valve implantation
- structural heart disease intervention
- transcatheter therapy
- tricuspid regurgitation
Fingerprint
Dive into the research topics of 'Heterotopic caval valve implantation in severe tricuspid regurgitation'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver